2 The abbreviations used are: CL, cutaneous leishmaniasis; MLF, miltefosine; KD, knockdown; ABC, ATP binding cassette; PMA, phorbol 12-myristate 13-acetate; PBMC, peripheral blood mononuclear cell.
Within its mammalian host, Leishmania resides and replicates as an intracellular parasite. The direct activity of antileishmanials must therefore depend on intracellular drug transport, metabolism, and accumulation within the host cell. In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL). Membrane transporter gene expression in primary human macrophages infected in vitro with Leishmania Viannia panamensis and exposed to MLF showed modulation of ABC and solute liquid carrier transporters gene transcripts. Among these, ABCA3, a lipid transporter, was significantly induced after exposure to MLF, and this induction was confirmed in primary macrophages from CL patients. Functional validation of MLF as a substrate for ABCA3 was performed by shRNA gene knockdown (KD) in THP-1 monocytes. Intracellular accumulation of radiolabeled MLF was significantly higher in ABCA3 KD macrophages. ABCA3 KD resulted in increased cytotoxicity induced by MLF exposure. ABCA3 gene expression inversely correlated with intracellular MLF content in primary macrophages from CL patients. ABCA3 KD reduced parasite survival during macrophage infection with an L. V. panamensis strain exhibiting low in vitro susceptibility to MLF. Confocal microscopy showed ABCA3 to be located in the cell membrane of resting macrophages and in intracellular compartments in L. V. panamensis-infected cells. These results provide evidence of ABCA3 as an MLF efflux transporter in human macrophages and support its role in the direct antileishmanial effect of this alkylphosphocholine drug.
Leishmania parasites are the causative agent of cutaneous leishmaniasis (CL) 2 and visceral leishmaniasis, neglected tropical diseases with a combined annual incidence of an estimated 1.5 million cases globally (1) . Among the scarce chemotherapeutic options available, antimonial drugs remain the first line treatment in most affected countries. However, loss of susceptibility against pentavalent antimonials shown in Leishmania isolates from both visceral leishmaniasis and CL patients, increased rates of therapeutic failure, and high toxicity, threaten its usefulness (2) . An alternative treatment option is the alkylphosphocholine miltefosine (MLF), the only oral drug available and registered for the treatment of CL and visceral leishmaniasis (3) . The response to MLF treatment during L. Viannia infections apparently varies among patients infected with different L. Viannia species, with cure rates that range from 60% in regions of Guatemala where L. V. braziliensis and Leishmania mexicana are common (4) , to 90% in Bolivia and Colombia in infections caused by L. V. braziliensis and L. V. panamensis, respectively (5, 6) . Although it has been suggested that the therapeutic response to MLF is potentially linked to species-specific loss of susceptibility (7, 8) , recent studies show a wide range of susceptibilities among clinical isolates of the same Leishmania species (9) , and therapeutic failure has been reported in visceral leishmaniasis patients infected with drug-susceptible strains (10) . We have recently shown that underexposure was associated with MLF treatment failure (11) . Together, these findings indicate that parasite factors, other than classical drug resistance, and host factors are critical to the efficacy of MLF treatment.
During human infection, Leishmania preferentially resides and replicates within macrophages. Thus, the direct activity of antileishmanial drugs is dependent upon effective drug delivery to host cells and to the intracellular compartments (phagolysosomes) inhabited by the parasite. However, which host factors contribute to the therapeutic response and how remain poorly understood. Our group and others have shown that transport and accumulation of drugs within human macrophages affect the antileishmanial activity of first line antimonials (12, 13) . The mechanisms regulating MLF trafficking within host macrophages and its role in drug exposure and direct drug activity against intracellular Leishmania remain unknown.
We have recently observed that intracellular MLF concentrations in peripheral blood mononuclear cells isolated from miltefosine-treated CL patients followed a similar kinetic profile as plasma MLF concentrations (14) . A trend of higher end of treatment intracellular concentrations versus plasma concentrations was observed, suggesting intracellular MLF accumulation in human leukocytes (14) . Because MLF is an amphipathic phospholipid molecule, it is expected to cross passively over lipid membranes of the cell (15, 16) . However, an additional carrier-mediated transport mechanism dependent on temperature and ATP has also been shown to contribute to MLF accumulation in human cells (15) . Overexpression of the ATP binding cassette (ABC) transporter MDR1 in cancer cell lines results in reduced sensitivity to MLF (17) . ABC transporters LMDR1/ LABCB4 (18, 19) , LiABCG4 (20) , and LiABCG6 (21) have also been shown to mediate MLF transport in Leishmania and have been implicated in MLF resistance. Thus, alterations in parasite and host cell drug transport could modify the antileishmanial effect of MLF. The purpose of this study was to identify the active carriers involved in transport and accumulation of miltefosine in human macrophages and to characterize their impact on intracellular drug-mediated parasite killing.
Experimental Procedures

Ethics Statement
This study was approved and monitored by the institutional review board for ethical conduct of research involving human subjects of the Centro Internacional de Entrenamiento e Investigaciones Médicas in accordance with national (resolution 008430, República de Colombia, Ministry of Health, 1993) and international (Declaration of Helsinki and amendments, World Medical Association, Fortaleza, Brazil, October 2013) guidelines. All individuals voluntarily participated in the study, and written informed consent was obtained from each participant.
Study Design and Study Subjects
This study was designed to identify MLF membrane transporters in human macrophages and to evaluate their effect in the antileishmanial activity of MLF, aiming to define host cell factors that alter drug exposure of intracellular Leishmania. To identify candidate molecules with putative MLF transport function, we profiled gene expression of membrane transporters modulated by Leishmania infection and exposure to MLF in primary macrophages from healthy individuals. Modulation of gene expression was confirmed in primary macrophages from CL patients. Functional validation was performed using shRNA gene knockdown in THP-1 monocytes. MLF transport function was assessed by measurement of intracellular drug concentrations, cytotoxicity, and intracellular parasite killing assays.
Adult patients (n ϭ 19) with parasitologically confirmed diagnosis of active CL with a time of evolution Ͻ6 months, 18 -65 years of age, and without apparent immune deficiencies (negative HIV test, no evidence of immunological disorder, nor treatment with medication having immunomodulating effects) participated in this study. Peripheral blood samples were obtained prior to initiation of antileishmanial treatment.
Reagents and Chemicals
MLF (Cayman Chemical Company, catalog no. 63280, lot no. 0410809-56) was dissolved in sterile DMSO following the manufacturer's instructions (50 mg/62,5 ml DMSO) and stored at Ϫ20°C until use. When indicated, MLF solutions were also prepared in PBS and used immediately after preparation. Working solutions were prepared in RPMI culture medium from the DMSO or PBS-dissolved stocks. Phorbol 12-myristate 13-acetate (PMA) was obtained from Sigma-Aldrich.
Cell Culture and Differentiation
Primary Macrophages-Peripheral blood samples were taken from study participants, and mononuclear cells (PBMCs) were obtained by separation using a Ficoll-Hypaque (Sigma-Aldrich) gradient, following the manufacturer's instructions. Macrophages were differentiated from PBMCs by adherence to cell culture plasticware as previously described (12) .
THP-1 Cell Line-The human pro-monocytic cell line THP-1 and derived cell lines were maintained at 1 ϫ 10 6 cells/ml in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated FBS, 100 g/ml streptomycin, and 100 units/ml penicillin at 37°C and 5% CO 2 . Cultured cells were differentiated using 250 ng/ml PMA for 3 h and washed with PBS, and adherence was allowed for 24 h.
Parasites, Infection, and Intracellular Parasite Survival Assays
MLF-susceptible L. (Viannia) panamensis promastigotes (EC 50 ϭ 2.9 M; 1.2 g/ml (22)) stably transfected with the luciferase reporter gene (L.p-LUC001) and MLF nonsusceptible L. V. panamensis (L.p-LUC056; EC 50 Ͼ 32 M; Ͼ13.0 g/ml, (22) ) were kept at 25°C in RPMI supplemented with 10% heat-inactivated FBS and 5 mg/ml hemin. L.p-LUC001 was maintained with additional 120 g/ml Geneticin and L.p-LUC056 cultured in the presence of 60 M MLF and 160 g/ml Geneticin. Macrophages were infected stationary phase promastigotes opsonized with human ABϩ serum at a 10:1 Leishmania-macrophage ratio for 2 h, washed twice with PBS, and incubated for 24 h at 34°C 5% CO 2 . After infection was established, the cells were exposed for 24 h to MLF (4 -16 M) or left untreated for additional 24 h. Intracellular parasite survival was measured by luciferase activity (23) .
Drug Transporter Quantitative PCR Arrays and Gene Expression Profiling
Screening of drug transporter gene expression was conducted as previously described (12) . The drug transporter Quantitative reverse transcriptase PCR array used was PAHS-070Z (SABiosciences-Qiagen). Selection of candidate genes was based on up-or down-regulation (Ϯ1.5-fold) following Leishmania infection and exposure to MLF at 16 M. Corroboration of expression of selected genes was conducted by quantitative RT-PCR in macrophages from CL patients (n ϭ 19) using TaqMan gene expression assays (Applied Biosystems): abcb1 (P-glycoprotein, Hs01070641_g1), abca3 (Hs00975530_m1), and gapdh (Hs99999905_m1). Reactions were run on a Bio-Rad CFX-96 detection platform. Ct values were normalized to gapdh, and gene expression was calculated by ⌬⌬Ct method and expressed as Log 2 fold change.
shRNA-mediated Transporter Gene Silencing in Host THP-1 Cells
A lentivirus-based system was used for shRNA-mediated gene silencing in THP-1 monocytes as previously described (24) . Four independent sets of lentiviral particles for shRNA gene knockdown of ABCA3 were purchased from Sigma-Aldrich (SHCLNV-NM_001089: TRCN0000303547, TRCN0000315649, TRCN0000315713, and TRCN0000315714) THP-1 monocytes were transduced at an average multiplicity of infection of five viral particles to one monocyte in medium containing 10 g/ml Polybrene. Transduced cells were selected and maintained under puromycin pressure (5 g/ml) for a minimum of 5 days. pLKO.1 (Addgene) empty vector transduced cells were used as negative control. Gene knockdown was assessed by quantitative RT-PCR prior to every experimental procedure and considered acceptable when knockdown was Ͼ50%, compared with empty vector transfected THP-1 cells. Gene knockdown was also confirmed at the protein level by flow cytometry. Briefly, 1 ϫ 10 6 monocytes were collected and washed with cold PBS and fixed with 0.5% formaldehyde for 30 min at 4°C. The cells were permeabilized with 0.2% PBS-Tween 20 for 15 min at 37°C, washed, and incubated with anti-human ABCA3 (Santa Cruz Biotechnology sc-134560) at a 1:50 ratio in FACS buffer containing 50% human ABϩ serum for 1 h at 4°C. The cells were then washed and incubated for 30 min with FITC-labeled anti-rabbit antibody (Jackson Immuno-Research). Staining was measured on a BD-Accuri C6 cytometer. A total of 50.000 events were acquired and analyzed in FlowJo Vx software (Tree Star).
Quantification of Intracellular MLF in THP-1 Cells
PMA-differentiated empty vector control and ABCA3 knockdown (ABCA3 KD ) THP-1 cells were infected with L. V. panamensis (or left uninfected) and exposed for 24 h to [ 14 C]MLF (kindly donated by Paladin Labs Inc.). Afterward, macrophages were washed three times with cold PBS-BSA (1%) to remove surface bound [ 14 C]MLF. The cells were collected and centrifuged at 800 ϫ g for 5 min, and the remaining pellet was resuspended in 50 l of PBS. Intracellular MLF was quantified by scintillation counting measured in a Chameleon multiplate reader (Hidex) and documented as cpm. The number of cpm was converted to concentration and quantified using a linear calibration curve with a range of 0.25-128 M MLF.
Quantification of Intracellular MLF in Primary Macrophages
Primary macrophages from CL patients were exposed in vitro to MLF (16 M and 32 M) for 24 h, washed with PBS-BSA (1%), and resuspended as described above. Intracellular MLF was quantified using a recently developed and validated LC-MS/MS method (14) . Briefly, macrophages were lysed with 62.5% methanol. The homogenized solution was evaporated and resuspended in plasma, after which MLF was quantified on a calibration curve prepared in blank human K-EDTA plasma.
This concentration was then back-calculated to total amount of miltefosine in the cell pellet.
Cytotoxicity Assays
PMA-differentiated ABCA3 KD and empty vector control cells, and primary human macrophages were exposed to a dose range of MLF for 24 h. Cell viability was assessed by 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (ATCC).
Phagocytosis Assays
THP-1 cell lines were cultured and differentiated in 12-well plates at 0.35 ϫ 10 6 cells/well in complete RPMI. The cells were incubated with 1 l of stock solution of 1.0-micron fluorescent latex beads (Fluoresbrite Carboxilate YG 1.00 m, catalog no. 15702, Polysciences, Inc.) for 2, 24, and 48 h. Adherent cells were detached with trypsin-EDTA, washed with PBS, and collected for FACS. A total of 20,000 events were acquired and analyzed.
Confocal Microscopy
PMA-differentiated THP-1 cells and primary human macrophages were plated on glass slides in 24-well plates, infected with L. V. panamensis transfected with green fluorescent protein and then exposed to 16 M MLF or left untreated. The cells were washed, fixed with 4% formaldehyde, permeabilized with PBS containing 0.05% Nonidet P-40 (Igepal) and 1% BSA for 5 min, and blocked with 5% skim milk in PBS. Subsequently the cells were incubated with anti ABCA3 antibody for 1 h in a humid chamber, washed twice with PBS, and incubated with Alexa Fluor 568 donkey anti-rabbit IgG (Molecular Probes, Invitrogen) for 1 h. The slides were mounted and analyzed on a Zeiss Observer Z1 microscope and images captured using Zen 2009 software.
Statistical Analysis
D'Agostino and Pearson's omnibus test (25) was used to test for departures of quantitative data from normal distributions. Differences in gene expression were tested with one-way analysis of variance and Tukey´s multiple comparisons test. Differences in variance for the remaining experiments were analyzed with unpaired t test. Statistical dependence of variables was determined by Spearman's rank correlation. A significance level of p Ͻ 0.05 was used for all statistical tests. Statistical analysis was performed using GraphPad Prism software (version 5).
Results
Exposure to Miltefosine Modulates Expression of Membrane
Transporters in Human Macrophages-To identify candidate proteins with putative MLF transport function in human macrophages, we evaluated the effect of MLF exposure on the modulation of expression of transporter genes in L. V. panamensis-infected primary human macrophages from healthy donors (n ϭ 3). Miltefosine concentrations used for all experiments were not toxic for either primary macrophages or THP-1 cells (Fig. 1 ). Expression of 84 transporter genes including members of the ABC transporters, solute liquid carriers, and aquaporins, was assessed by quantitative RT-PCR. As shown in Table 1 , both L. V. panamensis infection and exposure to MLF modulate the expression of membrane transporters in human macrophages. Four of nine ABC transporters modulated by exposure to MLF (ABCA1, ABCA3, ABCB1, and ABCD1) have been shown to transport lipids or lipid-related compounds (26) . Among these, expression of ABCA3 and ABCB1 was significantly higher in infected macrophages exposed to MLF ( Table  1 ). The ratio of ABCA3 expression between infected and infected and drug-exposed macrophages was the highest (Table  1) , followed by that of ABCB1. ABCA3 and ABCB1 expression was significantly induced by exposure to MLF in primary PBMC-derived macrophages from CL patients (n ϭ 19), whereas ABCA3 expression was down-regulated by L. V. panamensis infection (Fig. 2, A and B) . ABCA3 was also induced upon exposure to MLF dissolved in PBS, substantiating the drug mediated modulation of host cells gene expression ( Fig.  2C) .
ABCA3 Is a Miltefosine Transporter in Human Macrophages-In mammalian cells, ABCA3 functions as a lysosomal and lysosome-related organelle lipid transporter (27, 28) . Given that miltefosine is a phosphocholine analogue, we sought to explore the involvement of ABCA3 in intracellular MLF trafficking in human macrophages. We constructed an ABCA3 knockdown THP-1 cell line (ABCA3 KD ) using shRNA. More than 50% ABCA3 gene knockdown was achieved with TCR clone TCRN0000315713. Average gene knockdown evaluated in six independent biological replicas was 58 Ϯ 7%, and this was confirmed at the protein level by flow cytometry (Fig. 3A) ; further experiments were conducted with this transduced cell line. Measurement of intracellular [ 14 C]MLF showed a dose-dependent drug accumulation within THP-1 cells (Fig. 3B ). Higher accumulation of MLF was observed in ABCA3 KD cells compared with empty vector transfected controls. This difference a Expression data are shown as relative quantitations based on gene expression levels compared to uninfected and untreated macrophages from the same donor. Shown are genes that were up-or down-regulated beyond a threshold of Ϯ1.5-fold compared to control cells. The data are shown as mean values Ϯ S.D. (n ϭ 3). b Primary human macrophages infected with L. V. panamensis for 48 h. c Primary human macrophages infected with L. V. panamensis for 24 h followed by exposure to MLF 16 M for 24 h. d Two-tailed unpaired t test of the comparison between gene expression of infected and infected and drug treated macrophages. e Gene expression ratio between infected and drug-exposed cells over infected macrophages. was significant at drug concentrations of 8 and 16 M. In line with higher intracellular MLF accumulation, cytotoxicity assays showed significantly higher MLF-related cytotoxicity in ABCA3 KD cells (Fig. 3C) .
Intracellular MLF concentrations were also measured in PBMC-derived macrophages from CL patients (n ϭ 10). Macrophages were exposed in vitro to MLF (16 and 32 M) for 24 h. Intracellular drug accumulation was dose-dependent ( Fig.  4A) and unaffected by L. V. panamensis infection. MLF content measured in uninfected cells inversely correlated to drug induced expression of ABCA3 and ABCB1 (Fig. 4B ). However, no correlation was observed between gene expression and intracellular MLF in L. V. panamensis-infected cells (p ϭ 0.26 and p ϭ 0.1 for ABCA3 and ABCB1, respectively).
Macrophage ABCA3 Gene Knockdown Promotes MLF-mediated Intracellular Killing of Nonsusceptible L. V. panamensis-
The effect of host cell ABCA3 expression on MLF-mediated parasite killing was evaluated. Parasite killing was comparable when cells were exposed to MLF preparations in DMSO and PBS (Fig. 5A) . ABCA3 KD and empty vector control PMA-differentiated THP-1 cells were infected with MLF-susceptible and nonsusceptible L. V. panamensis. MLF-mediated parasite killing was dose-dependent. No difference in intracellular parasite killing of the MLF-susceptible line was observed among KD and control cells (Fig. 5, B and C) . However, MLF-non susceptible Leishmania was significantly killed in ABCA3 KD cells, whereas no drug-mediated killing was observed in empty vector controls (Fig. 5, D and E) .
The average parasite burden in untreated ABCA3 KD cells after infection with either MLF-susceptible or nonsusceptible parasites was 2-fold lower than control cells (Fig. 5, C and E) , suggesting an additional effect of this membrane transporter in parasite uptake, intracellular survival, or replication. We evaluated the phagocytosis capacity of ABCA3 KD cells using fluorescent latex beads. As shown in Fig. 6 , ABCA3 KD cells showed a reduced capacity to uptake latex beads reflected in lower fluorescence intensity, and this phenomenon was sustained in time (up to 48 h). These data support an additional influence of ABCA3 in macrophage phagocytosis.
Intracellular Localization of ABCA3 in Leishmania-infected Macrophages-THP-1 cells and primary human macrophages were infected with GFP-expressing L. V. panamensis and exposed to 16 M MLF. In uninfected and unexposed cells, the ABCA3 transporter was found primarily at the cell membrane ( Fig. 7) . Upon L. V. panamensis infection, ABCA3 localization was mainly intracellular in a vesicular pattern staining and in the proximity of Leishmania containing phagosomes in the THP-1 line. Exposure to MLF partially restored the cell membrane localization of ABCA3.
Discussion
The effect of antimicrobials that target intracellular pathogens is, among others, determined by the capacity of drugs to be internalized into host cells and to traffic to the intracellular compartment in which pathogens reside. Our group and others have shown that killing of intracellular Leishmania by in vitro exposure to antimonial drugs is affected by the nature of the host cell (29) and by differential expression and function of ABC transporters (12, 13) . In this study, we explored the role of human macrophages in the transport, accumulation, and exposure of intracellular Leishmania to MLF, the only oral drug available for the treatment of visceral and cutaneous leishmaniasis. Our results demonstrate the participation of ABCA3 in the transport of MLF across human macrophage membranes.
Gene expression profiles have been one of the most powerful tools to understand the mechanisms of action of bioactive compounds, the cellular response to drugs, and the identification of therapeutic targets and mechanisms of resistance (30, 31) . Pro-FIGURE 2. Expression of macrophage ABCA3 and ABCB1 is induced by exposure to miltefosine. ABCA3 (A) and ABCB1 (B) gene expression was evaluated in macrophages from CL patients (n ϭ 19) infected in vitro with L. V. panamensis (L.p) for 24 h and treated with 16 M miltefosine dissolved in DMSO (MLF) for subsequent 24 h or left untreated. Expression of ABCA3 was also measured in uninfected THP-1 cells exposed to increasing concentrations of MLF dissolved in PBS (C). Statistical differences were determined by one-way analysis of variance followed by Tukey's multiple comparisons test. Mean values are shown. NIL, untreated control.
ABCA3, a Miltefosine Transporter in Human Macrophages
filing the expression of membrane transporters modulated by L. V. panamensis infection and exposure to MLF suggested a possible contribution of ABCA1, ABCA3, and ABCD1 lipid transporters in MLF trafficking within human macrophages and supported the previously recognized role of ABCB1 in MLF efflux (17) . Although two solute liquid carriers, SLC7A11 and SLC3A1, were also induced by exposure to miltefosine, higher interindividual variability was observed and thus not selected for further functional validation.
ABCA3 gene knockdown in THP-1 cells showed that MLF is a substrate of this membrane transporter. ABCA3 is a cholesterol and phosphatidylcholine influx transporter (27, 32, 33) found in the membranes of lysosomes and lamellar bodies, and its function has been primarily related to surfactant lipid metabolism and lamellar body biogenesis (28, 32, 34) . Mutations in this transporter have been associated with surfactant dysfunction and respiratory diseases, especially in children (35) and recently its expression in lung cells has been reported to modulate susceptibility to cisplatin and paclitaxel (36) . Increased ABCA3 expression in mononuclear cells during acute myeloid leukemia has been shown to mediate chemoresistance by intravesicular drug sequestration (33) . The predominant plasma membrane localization of ABCA3 in macrophages, coupled to increased drug accumulation in the ABCA3 KD line and the inverse correlation between ABCA3 gene expression and intracellular MLF accumulation, suggests a function of ABCA3 as an efflux transporter in human macrophages. Following L. V. panamensis infection, ABCA3 was relocalized to intracel-lular compartments, potentially lysosomes as previously described (33) . Whether recruitment of this transporter to vesicular membranes promotes its delivery to the phagosomal membrane remains to be validated.
Unexpectedly, ABCA3 knockdown did not result in a significant difference in drug-mediated parasite killing of an MLFsusceptible L. V. panamensis strain. After 24 h of exposure to extracellular MLF concentrations as low as 4 M, average intracellular concentrations were 3.3 and 5 M in empty vector control and ABCA3 KD THP-1 cells, respectively. This, together with the low EC 50 of the MLF-susceptible strain (2.9 M; 1.2 g/ml (22) ), suggests that the intracellular drug concentrations achieved in either control or ABCA3 KD macrophages are sufficient to kill MLF-susceptible parasites. In contrast, the nonsusceptible L. V. panamensis strain used in this study has been shown to have an EC 50 value of Ͼ32 M (22) . The observed ϳ40% reduction in parasite load in ABCA3 KD cell in the presence of 16 M extracellular MLF is consistent with intracellular MLF concentrations that are toxic even to nonsusceptible strains achieved in ABCA3 KD cells. This indicates that increased drug accumulation within host macrophages could be exploited as a mechanism to partially revert nonsusceptibility phenotypes.
The role of ABCA3 during infection may not be restricted to MLF transport. ABCA3 knockdown decreased Leishmania uptake, potentially linked to reduced phagocytosis in ABCA3 KD cells. Interestingly, Ced-7, a homologue of ABCA3 in Caenorhabditis elegans, functions in the engulfment of cell corpses during programmed cell death (37) . Alterations in lipid transport could affect cell membrane composition, indirectly impacting on cell membrane-dependent processes such as endocytosis and phagocytosis (26) . Thus, reduced parasite burden in ABCA3 KD macrophages could be mediated by an additive effect of decreased Leishmania internalization and increased intracellular MLF accumulation and drug-mediated parasite killing.
Identification of a role for ABCA3 in reducing the antileishmanial activity of miltefosine raises the possibility of inhibiting ABCA3 to improve treatment success. Inhibition of ABCA3 expression has been reported to occur upon exposure of acute myeloid leukemia cells to the nonsteroidal anti-in-flammatory drug indomethacin (38) . The immunomodulatory properties of indomethacin make it unsuitable as component of Leishmania therapy, but a better understanding of how it affects ABCA3 expression may enable discovery of other, more suitable repressors.
We have previously reported an inverse correlation between Leishmania ABCA3 gene expression in amastigotes and MLF susceptibility, supporting the possibility that higher expression of vesicular ABCA3 in the parasite could promote susceptibility through increased drug accumulation (22) . Although not functionally validated, this hypothesis would suggest that ABCA3 inhibitors could induce drug resistance in the parasite. However, the amino acid sequences of Leishmania ABCA3 (retrieved from either L.V. braziliensis, Leishmania major, or Leishmania infantum genomes) and mammalian ABCA3 share only 30% sequence identity; this divergence supports targeted intervention of host ABCA3. Conceivably, pharmacological modulation of host ABCA3 and potentially other ABC lipid transporters could potentiate the antileishmanial effect of miltefosine for the treatment of infections caused by Leishmania strains of diverse drug susceptibilities.
Here we report the expression of ABCA3 in human macrophages, its role in the transport of miltefosine, and its modulation during exposure to miltefosine. Our results provide evidence in support of the central role of host cell drug transport and accumulation in the direct activity of drugs that target intracellular pathogens. Characterization of the molecular mechanisms that mediate host cell drug influx, efflux, and trafficking between intracellular compartments increases our understanding of the pharmacokinetic-pharmacodynamic relationships of drugs active against intracellular pathogens.
More importantly, it allows for identification of novel hostdirected therapeutic strategies to optimize intracellular exposure and thus efficacy of both available and future antileishmanial drugs. 
